Literature DB >> 18668635

Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis.

Christel Renoux, Samy Suissa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18668635     DOI： 10.1002/ana.21352

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  8 in total

Review 1.  Can we measure long-term treatment effects in multiple sclerosis?

Authors:  Maria Pia Sormani; Paolo Bruzzi
Journal:  Nat Rev Neurol       Date:  2014-12-23       Impact factor: 42.937

2.  Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.

Authors:  Mohammad Ehsanul Karim; Paul Gustafson; John Petkau; Helen Tremlett
Journal:  Am J Epidemiol       Date:  2016-07-25       Impact factor: 4.897

3.  Immortal time bias does not invalidate the association of self-monitoring of blood glucose with better survival of patients with type 2 diabetes in the epidemiological study ROSSO (Retrolective Study: Self-monitoring of Blood Glucose and Outcome in Patients with Type 2 Diabetes).

Authors:  B Schneider; S Martin; W A Scherbaum; L Heinemann; V Lodwig; H Kolb
Journal:  Diabetologia       Date:  2010-11-20       Impact factor: 10.122

4.  Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

Authors:  Mohammad Ehsanul Karim; Paul Gustafson; John Petkau; Yinshan Zhao; Afsaneh Shirani; Elaine Kingwell; Charity Evans; Mia van der Kop; Joel Oger; Helen Tremlett
Journal:  Am J Epidemiol       Date:  2014-06-17       Impact factor: 4.897

5.  Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure.

Authors:  Michelle Samuel; Michal Abrahamowicz; Jacqueline Joza; Marie-Eve Beauchamp; Vidal Essebag; Louise Pilote
Journal:  Europace       Date:  2020-05-01       Impact factor: 5.214

6.  Beta-interferon exposure and onset of secondary progressive multiple sclerosis.

Authors:  T Zhang; A Shirani; Y Zhao; M E Karim; P Gustafson; J Petkau; C Evans; E Kingwell; M van der Kop; F Zhu; J Oger; H Tremlett
Journal:  Eur J Neurol       Date:  2015-04-06       Impact factor: 6.089

7.  Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Authors:  Francisco Coret; Francisco C Pérez-Miralles; Francisco Gascón; Carmen Alcalá; Arantxa Navarré; Ana Bernad; Isabel Boscá; Matilde Escutia; Sara Gil-Perotin; Bonaventura Casanova
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-06-26

8.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.